Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis

Company To Initially Target 70 Cancer Centers

The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.

Form close up, fountain pen and approved stamped on a document. Soft focus. — Blueprint Medicines received FDA approval for Ayvakit in advanced systemic mastocytosis • Source: Shutterstock

Blueprint Medicines Corporation’s newly approved Ayvakit (avapritinib) appears well-positioned to challenge its only competitor in advanced systemic mastocytosis (SM), Novartis AG’s Rydapt (midostaurin). Blueprint is planning an initial rollout to specialized cancer centers and an education push to facilitate moving the drug into community oncology settings, similar to its strategy for the drug in gastrointestinal stromal tumor (GIST).

Cambridge, MA-based Blueprint announced 16 June that the FDA had approved Ayvakit for advanced SM, including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

29 May 2025

• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

29 May 2025

• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

29 May 2025

• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.